Bicycle Therapeutics plc (BCYC) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
BCYC Insider Trading Activity
BCYC Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $21,230,385 | 2 | 6 |
Sells | $960,483 | 29 | 94 |
Related Transactions
| BAKER BROS. ADVISORS LP | 2 | $21.23M | 0 | $0 | $21.23M | |
| Keen Nicholas | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 1 | $15,300 | $-15,300 |
| Young Alethia | Chief Financial Officer | 0 | $0 | 1 | $19,656 | $-19,656 |
| Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 0 | $0 | 4 | $40,330 | $-40,330 |
| Arroyo Santiago | CHIEF DEVELOPMENT OFFICER | 0 | $0 | 1 | $69,647 | $-69,647 |
| Crockett Nigel | CHIEF BUSINESS OFFICER | 0 | $0 | 4 | $90,829 | $-90,829 |
| Skynner Michael | CHIEF TECHNOLOGY OFFICER | 0 | $0 | 4 | $100,748 | $-100,748 |
| Milnes Alistair | CHIEF OPERATING OFFICER | 0 | $0 | 4 | $118,939 | $-118,939 |
| Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER | 0 | $0 | 6 | $197,853 | $-197,853 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER | 0 | $0 | 4 | $307,182 | $-307,182 |
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Insider Activity of Bicycle Therapeutics plc
Over the last 12 months, insiders at Bicycle Therapeutics plc have bought $21.23M and sold $960,483 worth of Bicycle Therapeutics plc stock.
On average, over the past 5 years, insiders at Bicycle Therapeutics plc have bought $21.23M and sold $6.61M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP () — $21.23M.
The last purchase of 500,000 shares for transaction amount of $7.67M was made by BAKER BROS. ADVISORS LP () on 2024‑12‑16.
List of Insider Buy and Sell Transactions, Bicycle Therapeutics plc
| 2025-01-06 | Sale | Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER | 2,686 0.0039% | $15.00 | $40,290 | -33.57% | |
| 2025-01-03 | Sale | Lee Kevin | CHIEF EXECUTIVE OFFICER | 3,092 0.0044% | $14.75 | $45,607 | -32.98% | |
| 2025-01-03 | Sale | Skynner Michael | CHIEF TECHNOLOGY OFFICER | 936 0.0013% | $14.75 | $13,806 | -32.98% | |
| 2025-01-03 | Sale | Milnes Alistair | CHIEF OPERATING OFFICER | 936 0.0013% | $14.75 | $13,806 | -32.98% | |
| 2025-01-03 | Sale | Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 239 0.0003% | $14.75 | $3,525 | -32.98% | |
| 2025-01-03 | Sale | Crockett Nigel | CHIEF BUSINESS OFFICER | 936 0.0013% | $14.75 | $13,806 | -32.98% | |
| 2025-01-03 | Sale | Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER | 159 0.0002% | $14.75 | $2,345 | -32.98% | |
| 2025-01-02 | Sale | Lee Kevin | CHIEF EXECUTIVE OFFICER | 9,038 0.013% | $14.09 | $127,345 | -29.94% | |
| 2025-01-02 | Sale | Skynner Michael | CHIEF TECHNOLOGY OFFICER | 3,287 0.0047% | $14.09 | $46,314 | -29.94% | |
| 2025-01-02 | Sale | Milnes Alistair | CHIEF OPERATING OFFICER | 4,578 0.0066% | $14.09 | $64,504 | -29.94% | |
| 2025-01-02 | Sale | Arroyo Santiago | CHIEF DEVELOPMENT OFFICER | 4,943 0.0071% | $14.09 | $69,647 | -29.94% | |
| 2025-01-02 | Sale | Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 1,879 0.0027% | $14.09 | $26,475 | -29.94% | |
| 2025-01-02 | Sale | Crockett Nigel | CHIEF BUSINESS OFFICER | 2,583 0.0037% | $14.09 | $36,394 | -29.94% | |
| 2025-01-02 | Sale | Young Alethia | Chief Financial Officer | 1,395 0.002% | $14.09 | $19,656 | -29.94% | |
| 2025-01-02 | Sale | Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER | 1,750 0.0025% | $14.09 | $24,658 | -29.94% | |
| 2024-12-16 | BAKER BROS. ADVISORS LP | 500,000 0.7341% | $15.34 | $7.67M | -30.75% | |||
| 2024-12-13 | BAKER BROS. ADVISORS LP | 985,397 1.3409% | $13.76 | $13.56M | -23.53% | |||
| 2024-11-11 | Sale | Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER | 4,944 0.0073% | $25.13 | $124,248 | -49.92% | |
| 2024-10-03 | Sale | Lee Kevin | CHIEF EXECUTIVE OFFICER | 3,212 0.0044% | $22.26 | $71,499 | -40.65% | |
| 2024-10-03 | Sale | Skynner Michael | CHIEF TECHNOLOGY OFFICER | 972 0.0013% | $22.26 | $21,637 | -40.65% |
Insider Historical Profitability
| BAKER BROS. ADVISORS LP | 9995274 14.4435% | $80.06M | 2 | 0 | ||
| Lee Kevin | CHIEF EXECUTIVE OFFICER | 491934 0.7109% | $3.94M | 0 | 39 | |
| Skynner Michael | CHIEF TECHNOLOGY OFFICER | 123722 0.1788% | $991,013.22 | 0 | 10 | |
| Milnes Alistair | CHIEF OPERATING OFFICER | 99788 0.1442% | $799,301.88 | 0 | 10 | |
| Arroyo Santiago | CHIEF DEVELOPMENT OFFICER | 69057 0.0998% | $553,146.57 | 0 | 1 | |
| Keen Nicholas | CHIEF SCIENTIFIC OFFICER | 62024 0.0896% | $496,812.24 | 0 | 16 | |
| Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 55280 0.0799% | $442,792.80 | 0 | 5 | |
| Crockett Nigel | CHIEF BUSINESS OFFICER | 51053 0.0738% | $408,934.53 | 0 | 13 | |
| Young Alethia | Chief Financial Officer | 45605 0.0659% | $365,296.05 | 0 | 1 | |
| Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER | 32146 0.0465% | $257,489.46 | 0 | 10 | |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 10 percent owner | 1957961 2.8293% | $15.68M | 1 | 0 | <0.0001% |
| HARLAND DEBORAH | director | 1915275 2.7676% | $15.34M | 1 | 0 | <0.0001% |
| GLAXOSMITHKLINE PLC | 10 percent owner | 1910531 2.7608% | $15.3M | 1 | 2 | <0.0001% |
| SVLSF V, LLC | 10 percent owner | 1875637 2.7104% | $15.02M | 1 | 0 | <0.0001% |
| Novartis Bioventures Ltd | 10 percent owner | 1769641 2.5572% | $14.17M | 1 | 0 | <0.0001% |
| Anstey Michael | director | 1751437 2.5309% | $14.03M | 1 | 0 | <0.0001% |
| Cambridge Innovation Capital (Jersey) Ltd | 10 percent owner | 1751437 2.5309% | $14.03M | 1 | 0 | <0.0001% |
| NG CAROLYN | director | 571429 0.8257% | $4.58M | 1 | 0 | <0.0001% |
| BINGHAM KATE | director | 38708 0.0559% | $310,051.08 | 1 | 2 | <0.0001% |
| Smethurst Dominic | Chief Medical Officer | 36699 0.053% | $293,958.99 | 0 | 1 | |
| Kalowski Lee | President and CFO | 30309 0.0438% | $242,775.09 | 0 | 13 | |
| Legault Pierre | director | 0 0% | $0 | 0 | 8 |
Historical Insider Profitability vs. Competitors
$14,527,743 | 76 | 38.40% | $516.52M | |
$47,282,828 | 47 | -17.38% | $542.8M | |
$28,907,358 | 35 | 41.41% | $579.33M | |
$94,912,877 | 34 | -7.15% | $563.77M | |
$149,456,352 | 27 | -8.77% | $611.89M | |
$169,638,586 | 22 | 30.82% | $569.36M | |
$124,557,176 | 16 | 29.13% | $571.45M | |
$18,945,106 | 14 | -27.94% | $485.98M | |
$103,194,328 | 13 | 9.02% | $627.43M | |
$278,247,340 | 12 | 58.08% | $622.07M | |
$92,357,691 | 12 | 87.24% | $551.96M | |
$11,541,901 | 10 | 8.07% | $496.07M | |
$94,976,497 | 10 | -10.72% | $490.83M | |
$20,499,451 | 9 | 71.54% | $555.62M | |
Bicycle Therapeutics plc (BCYC) | $91,721,700 | 9 | -13.73% | $554.31M |
$49,165,200 | 7 | 12.92% | $539.87M | |
$73,280,625 | 6 | -41.09% | $513.38M | |
$3,200,000 | 5 | -11.36% | $474.9M | |
$13,900 | 1 | -39.25% | $605.08M |
BCYC Institutional Investors: Active Positions
| Increased Positions | 48 | +35.56% | 11M | +26.59% |
| Decreased Positions | 59 | -43.7% | 11M | -25.45% |
| New Positions | 14 | New | 3M | New |
| Sold Out Positions | 26 | Sold Out | 6M | Sold Out |
| Total Postitions | 124 | -8.15% | 43M | +1.13% |
BCYC Ownership Change vs Market
Institutional Investor Ownership
| Baker Bros. Advisors Lp | $101,234.00 | 22.68% | 10.89M | +1M | +15.8% | 2024-12-31 |
| Point72 Asset Management, L.P. | $42,361.00 | 9.49% | 4.55M | +4M | +406.21% | 2024-12-31 |
| Fcpm Iii Services B.V. | $32,107.00 | 7.19% | 3.45M | +1M | +47.54% | 2024-12-31 |
| Westfield Capital Management Co Lp | $24,276.00 | 5.44% | 2.61M | +759,392 | +41.03% | 2024-12-31 |
| Armistice Capital, Llc | $20,423.00 | 4.58% | 2.2M | +240,000 | +12.27% | 2024-12-31 |
| Siren, L.L.C. | $17,106.00 | 3.83% | 1.84M | +2M | New | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $14,742.00 | 3.3% | 1.59M | -136,913 | -7.95% | 2024-12-31 |
| Deep Track Capital, Lp | $11,868.00 | 2.66% | 1.28M | -2M | -64.03% | 2024-12-31 |
| Tybourne Capital Management (Hk) Ltd | $11,807.00 | 2.65% | 1.27M | -125,000 | -8.96% | 2024-12-31 |
| Bnp Paribas Asset Management Holding S.A. | $10,748.00 | 2.41% | 1.16M | +395,764 | +52.08% | 2024-12-31 |